title: Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan.
abstract: Chronic lymphocytic leukemia (CLL) is a rare disease in Japan. Recent advances in molecular biology, diagnostic criteria and classification of CLL have reinforced the concept of each category of CLL as a distinct entity. Since there have been no recent studies on the incidence and prevalence of CLL in Japan, the Kyushu Hematology Organization for Treatment (K-HOT) Study Group conducted two studies of CLL. One study is a prospective registration of newly diagnosed hematological disorders, which gave us some idea of the incidence of CLL in our region (Kyushu island) where adult T-cell leukemia is endemic. A total of 677 patients with hematological disorders were registered over a 6-month period and 11 patients were diagnosed as having CLL among 182 leukemia patients. This amounts to 6% of all leukemias, which is twice as frequent as previously reported in Japan. The other study is a retrospective analysis of CLL. Eleven institutions of the K-HOT Group analysed their diagnostic records of chronic lymphoid leukemia, and 145 patients with CLL were found over a period of 3-12 yr. After the data were reviewed 11 patients were excluded through having a different type of leukemia. The proportion of chronic B-cell lymphoid leukemia was 73% (98/134), while that of T-cell leukemia was 18% (24/134). The proportion of T-cell chronic leukemia was 5-6 times higher than that in Western countries. Two institutions had a complete database on hematological disorders. From this database, the annual incidence of CLL was estimated to be 0.48 per 100 000. Thus, the incidence of CLL in Japan is at least 4-5 times lower than that in Western countries, suggesting that chronic B-cell leukemia is really rare, but chronic leukemia of T-cell lineage develops in Japan as frequently as in Western societies. Further investigation is required to delineate why the incidence of B-CLL is so low in Japan.
authors.affiliation: Department of Internal Medicine, Fukuoka University Hospital, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: H
authors.initials: H
authors.lastname: Sawada
authors.forename: Y
authors.initials: Y
authors.lastname: Izumi
authors.forename: T
authors.initials: T
authors.lastname: Fukuda
authors.forename: A
authors.initials: A
authors.lastname: Utsunomiya
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
authors.forename: N
authors.initials: N
authors.lastname: Uike
authors.forename: J
authors.initials: J
authors.lastname: Tsukada
authors.forename: F
authors.initials: F
authors.lastname: Kawano
authors.forename: T
authors.initials: T
authors.lastname: Shibuya
authors.forename: H
authors.initials: H
authors.lastname: Gondo
authors.forename: S
authors.initials: S
authors.lastname: Okamura
authors.forename: J
authors.initials: J
authors.lastname: Suzumiya
mesh_terms: D000328:Adult; D000368:Aged; D016208:Databases, Factual; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000453:epidemiology* / Q000473:pathology; D015461:Leukemia, Prolymphocytic, T-Cell / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged